Movement Alert｜Alnylam Pharmaceuticals Falls 5.21% in Regular Trading, Amvuttra Faces 340B Reimbursement Policy Uncertainty

Market Focus10-31

On October 31, Alnylam Pharmaceuticals fell 5.21% in Regular Trading, trading at $165.08 per share, with turnover of $7.44 billion.

The move coincided with investor concern over near-term risk to Amvuttra tied to potential changes in the 340B reimbursement framework, which analysts said could pressure hospital utilization starting in 2027.

Recent commentary also added that Alnylam’s third-quarter update was disappointing because transthyretin revenue is now expected to trend toward the low end of its $4.2 billion to $4.5 billion guidance range. While Amvuttra revenue was broadly in line, the quarter benefited from favorable inventory dynamics and a one-time gross-to-net adjustment, reinforcing caution around the durability of growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment